Castle Biosciences, Inc. (CSTL) stock analysis
Healthcare · Diagnostics & Research
From the 10-K filed 2026-02-26
Business type: Asset play
How it makes money
Castle Biosciences earns revenue by selling proprietary molecular diagnostic and risk stratification tests to clinicians and patients, heavily reliant on Medicare reimbursement.
Castle Biosciences generates revenue by offering specialized testing solutions across dermatology, gastroenterology, and ophthalmology, helping clinicians make personalized treatment and diagnosis decisions. A significant portion of this income is tied directly to government and commercial payors, with Medicare representing 44% and 47% of total revenue for the years ended December 31, 2025 and 2024, respectively. Additionally, a single commercial payor accounted for 16% of patient revenue for the year ended December 31, 2025. Because reimbursement rates and coverage decisions vary, the company measures variable consideration using historical collection rates and expected value methods, which introduces estimation uncertainty that can impact reported earnings period over period.
What protects it: the moat
Management claims that proprietary technology, peer-reviewed clinical validation studies, and Advanced Diagnostic Laboratory Test status protect its market position.
The company asserts protection through intellectual property, extensive clinical data, and regulatory designations such as Advanced Diagnostic Laboratory Test status granted by the Centers for Medicare and Medicaid Services. Achieving this status means each test has demonstrated it predicts individual patient conditions or therapeutic responses using an empirically derived algorithm, while providing new clinical diagnostic information. Furthermore, management cites peer-reviewed publications supporting analytical and clinical validity as a barrier, though the filing primarily presents these factors as management's strategic claims rather than insurmountable economic moats.
What growth costs
The filing does not detail specific ongoing capital expenditure figures required to maintain and grow earnings.
The provided text outlines commercial expansion efforts, such as the limited launch of the AdvanceAD-Tx test in November 2025 and the acquisition of Previse to enhance Barrett's esophagus capabilities, but it does not disclose specific financial expenditures for maintaining or growing operations.
What could damage it
If major third-party payors significantly reduce reimbursement or deny coverage, revenue would drop and permanently impair financial results.
Castle Biosciences depends heavily on key third-party payors, notably Medicare and select commercial insurers. If these entities decide to significantly reduce reimbursement rates, attempt to recover previously paid amounts, or refuse favorable coverage decisions, the company would experience an immediate and severe contraction in realized revenue, permanently damaging its financial condition and operating results.
About Castle Biosciences, Inc.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.